Oruka Therapeutics Inc (ORKA)

Currency in USD
95.81
-1.76(-1.80%)
Closed·
97.00+1.19(+1.24%)
·
ORKA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
93.3097.24
52 wk Range
25.23115.52
Key Statistics
Prev. Close
95.81
Open
95.86
Day's Range
93.3-97.24
52 wk Range
25.23-115.52
Volume
1.98M
Average Volume (3m)
962.75K
1-Year Change
227.1082%
Book Value / Share
18.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORKA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
156.17
Upside
+63.00%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Oruka Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 156.17
(+63.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy133.00+38.82%-Maintain19-11-2026
H.C. Wainwright
Buy120.00+25.25%-Maintain27-10-2026
Guggenheim
Buy200.00+108.75%-Maintain26-10-2026
Piper Sandler
Buy180.00+87.87%-Maintain07-10-2026
H.C. Wainwright
Buy120.00+25.25%-Maintain24-09-2026

Earnings

Latest Release
09-11-2026
EPS / Forecast
-0.63 / -0.60
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ORKA Income Statement

Compare ORKA to Peers and Sector

Metrics to compare
ORKA
Peers
Sector
Relationship
P/E Ratio
−49.8x−1.7x−0.2x
PEG Ratio
5.28−0.010.00
Price/Book
5.4x1.9x2.6x
Price / LTM Sales
-124.2x2.6x
Upside (Analyst Target)
63.0%172.6%76.9%
Fair Value Upside
Unlock20.3%14.9%Unlock

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
33.57M49.50%3.21B
Other Institutional Investors
56.39M50.50%5.40B
Public Companies & Retail Investors
0.000.00%0.00
Total
89.96M100.00%8.61B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.96%1,01,48,8679,71,653
BlackRock, Inc.7.36%49,90,1814,77,760

FAQ

What Is the Oruka Therapeutics (ORKA) Share Price Today?

The Oruka Therapeutics share price today is 95.81.

What is the current Oruka Therapeutics (ORKA) share price and day range?

As of 21-11-2026, the Oruka Therapeutics share price is 95.81, with a previous close of 95.81. The share price has ranged from 93.30 to 97.24 today, while the 52-week range spans from 25.23 to 115.52.

What Is the Oruka Therapeutics Market Cap?

As of today, Oruka Therapeutics market cap is 6.62B.

What Is the Oruka Therapeutics (ORKA) Share Price Target?

The average 12-month share price target for Oruka Therapeutics is 156.17, with a high estimate of 200 and a low estimate of 117. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +63.00% Upside potential.

What Is Oruka Therapeutics's Earnings Per Share (TTM)?

The Oruka Therapeutics EPS (TTM) is -2.13.

When Is the Next Oruka Therapeutics Earnings Date?

Oruka Therapeutics will release its next earnings report on 11-03-2027.

From a Technical Analysis Perspective, Is ORKA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Oruka Therapeutics Trade On?

Oruka Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Oruka Therapeutics?

The stock symbol for Oruka Therapeutics is "ORKA."

How Many Times Has Oruka Therapeutics Stock Split?

Oruka Therapeutics has split 6 times.

What Is the ORKA Premarket Price?

ORKA's last pre-market stock price is 96.07. The pre-market share volume is 1,210.00, and the stock has changed by -1.50, or -1.54%.

What Is the ORKA After Hours Price?

ORKA's last after hours stock price is 97.00, the stock has changed by 1.19, or 1.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.